About Genocea

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea used ATLAS to identify the antigens in its lead clinical candidate, GEN-003, an investigational immunotherapy to treat genital herpes, and is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines and to identify T cell response signatures of cancer patients treated with checkpoint blockade therapies to potentially improve clinical practice. Genocea expects GEN-003 to be ready to begin Phase 3 development and to file an Investigational New Drug (IND) application for its neoantigen cancer vaccine candidate GEN-009 by the end of 2017.

adjusted-apc-t-cell-image2

Stock Quote

NASDAQ GNCA
$5.22
- 0.05 (-0.95%)


0.00M

Volume

$5.30

Day High

$5.22

Day Low

Sep 21, 2017 ET on 9:36 AM Delayed at least 20 minutes.

Stock Chart



Webcasts

Sep 27, 2017 at 10:20 AM ET